Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview
Open accessThe DOI matches its Crossref record; 131 of the 136 references it cites were found in a registry or an index.
Abstract
Irinotecan has been used in the treatment of various malignancies for many years. Still, the knowledge regarding this drug is expanding. The pharmacogenetics of the drug is the crucial component of response to irinotecan. Furthermore, new formulations of the drug are introduced in order to better deliver the drug and avoid potentially life-threatening side effects. Here, we give a comprehensive overview on irinotecan’s molecular mode of action, metabolism, pharmacogenetics, and toxicity. Moreover, this article features clinically used combinations of the drug with other anticancer agents and introduces novel formulations of drugs (e.g., liposomal formulations, dendrimers, and nanoparticles). It also outlines crucial mechanisms of tumor cells’ resistance to the active metabolite, ethyl-10-hydroxy-camptothecin (SN-38). We are sure that the article will constitute an important source of information for both new researchers in the field of irinotecan chemotherapy and professionals or clinicians who are interested in the topic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Mechanisms of action for human topoisomerases. (A) Topoisomerase IA binds to DNA at a particular binding site, and then claves one strand, forming a transient 5′-phosphotyrosyl bond. The other DNA strand is transferred through the resultant break, allowing DNA to relax. Religation ends the process. (B) Toposiomerase IB works in a controlled rotation mechanism and in contrast to type IA enzymes forms a 3′-phosphotyrosyl bond with a DNA molecule. Both type I (A&B) topoisomerases do not require ATP hydrolysis as a source of energy. (C) Topoisomerase II binds to both ends of the DNA molecule, forms a double-strand break, and passes a segment of dsDNA through. This reaction is ATP-dependent [19].](https://figures.cochat.ai/paper-figures/7f178116e98944b58d61966403e83683/irinotecanstill-an-important-player-in-cancer-chemotherapy-a-comprehensive-figure-1.jpg)


![Figure 4 Mechanisms of cell death induced by irinotecan. The ternary irinotecan–topoisomerase I–nicked DNA complex with topoisomerase I (Topo I) inhibitor (SN-38) disables religation of the nicked strand and prevents topoisomerase release. Collision of the formed complex with advancing replication forks results in the formation of double-strand breaks (DSBs). This is followed by DNA damage response (DDR) signaling and TP53-induced gene expression of pro-apoptotic genes such as apoptosis regulator (BAX), phorbol-12-myristate-13-acetate-induced protein 1 (NOXA), or p53 up-regulated modulator of apoptosis (PUMA). Furthermore, down-regulation of the Bcl-2-like protein 1 isoform protein (BCL-xL) protein allows BAX and Bcl-2 homologous antagonist (BAK) embedding into the mitochondrial membrane and the formation of pores that allow the release of cytochrome C (cytC) from mitochondria and the subsequent formation of apoptosome with apoptotic protease-activating factor 1 (APAF-1) protein and procaspase-9. The activation of procaspase to caspase 9 (Casp-9) results in proteolytic cleavage and the conversion of procaspase 3 into active caspase 3 (Casp-3), which executes apoptosis [37,38,44,49,51].](https://figures.cochat.ai/paper-figures/e0271a41931a4560ab503b6a9b0123a1/irinotecanstill-an-important-player-in-cancer-chemotherapy-a-comprehensive-figure-4.jpg)
![Figure 5 Overview of irinotecan metabolism. CPT-11 is a prodrug that is converted to active metabolite ethyl-10-hydroxy-camptothecin (SN-38) by liver carboxylesterase converting enzymes (CES1/2) and is then transported to the liver by 1B1 polypeptide (OATP1B1) and inactivated by microsomal uridine 5′-diphospho-glucuronosyltransferase enzymes (UGTs): UGT1A1 and UGT1A9. Irinotecan is transported to bile by a group of the ATP-binding cassette transporters (ABC transporters): ABCB1, ABCC1, ABCC2, and ABCG2. Irinotecan is efficiently metabolized by cytochrome P450 enzymes: CYP3A4 and CYP3A5. This results in the generation of less active metabolites APC (7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin) and NPC (7-ethyl-10-[4-amino-1-piperidino] carbonyloxycamptothecin). NPC (but not APC) can be further converted to SN-38 by CES1, and CES2 gut microbiota may also participate in irinotecan metabolism by the production of β-glucuronidase, which catalyzes the breakdown of SN-38G to SN-38. The inhibition of topoisomerase I (TOP1) results in DNA damage, replication fork arrest, and apoptotic cell death [53,54,55,56,57,58,59,60,61,62].](https://figures.cochat.ai/paper-figures/5036a4be7c55479baa6b8b63ea3ebd23/irinotecanstill-an-important-player-in-cancer-chemotherapy-a-comprehensive-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Irinotecan (IRI) is a chemotherapeutic agent that inhibits topoisomerase I activity, which in turn inhibits both DNA replication and transcription49.”
From A statistical framework for high-content phenotypic profiling using cellular feature distributions (2022) · cites this paper as [49]
Experimental — accuracy not yet measuredIn the citing paper
“Irinotecan exerts a cytotoxic effect by inhibiting DNA replication and transcription by targeting topoisomerase 1 (TOP-1) [87].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apoptosis: A Review of Programmed Cell Death
Elmore, S. (2007) · Toxicologic Pathology · doi:10.1080/01926230701320337 · Cited by 13,853
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
DNA Topoisomerases: Structure, Function, and Mechanism
Champoux, J. J. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.369 · Cited by 2,743
Cellular roles of DNA topoisomerases: a molecular perspective
Wang, J. C. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm831 · Cited by 2,353
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Mechanisms of Multidrug Resistance in Cancer Chemotherapy
Bukowski, K., Kciuk, M., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093233 · Cited by 1,757
Self-citationVauthey, J.-N., Pawlik, T. M., Ribero, D., Wu, T.-T., Zorzi, D., Hoff, P. M., Xiong, H. Q., Eng, C., Lauwers, G. Y., Mino-Kenudson, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3074 · Cited by 1,300
Cited by
Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
Kciuk, M., Gielecińska, A., Mujwar, S., Kołat, D., Kałuzińska-Kołat, Ż., Celik, I., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040659 · Cited by 810
“Supercoiled DNA emerging during the above-mentioned processes can unwind and efficiently function as a template upon the introduction of single- or double-strand breaks (SSBs or DSBs) by topoisomerase type I and II enzymes, respectively [67].”
BackgroundSelf-citationStatus and Challenges of Plant-Anticancer Compounds in Cancer Treatment
Garcia-Oliveira, P., Otero, P., Pereira, A. G., Chamorro, F., Carpena, M., Echave, J., Fraga-Corral, M., Simal-Gandara, J., & Prieto, M. A. (2021) · Pharmaceuticals · doi:10.3390/ph14020157 · Cited by 303
“These issues could be solved by new drug formulations containing nanoparticles, polymer conjugates, dendrimers, peptides, and carbohydrates [64].”
BackgroundPEGylated therapeutics in the clinic
Gao, Y., Joshi, M., Zhao, Z., & Mitragotri, S. (2024) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10600 · Cited by 233
“124,125 The need for PEGylation of traditionally considered small molecule drugs is pressing, given that many effective small molecule drugs, such as irinotecan, 126 suffer from undesirable pharmacokinetic profiles.”
BackgroundTreatment for liver cancer: From sorafenib to natural products
Man, S., Luo, C., Yan, M., Zhao, G., Ma, L., & Gao, W. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113690 · Cited by 177
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Microbiota-Host-Irinotecan Axis: A New Insight Toward Irinotecan Chemotherapy
Yue, B., Gao, R., Wang, Z., & Dou, W. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.710945 · Cited by 92
Anti-Cancer Activity of Sustained Release Capsaicin Formulations
Merritt, J. C., Richbart, S. D., Moles, E. G., Cox, A. J., Brown, K. C., Miles, S. L., Finch, P. T., Hess, J. A., Tirona, M. T., Valentovic, M. A., et al. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108177 · Cited by 94
Role of plant derived bioactive compounds against cancer
Roy, A., Datta, S., Bhatia, K. S., Bhumika, Jha, P., & Prasad, R. (2021) · South African Journal of Botany · doi:10.1016/j.sajb.2021.10.015 · Cited by 66
Updates in KMT2A Gene Rearrangement in Pediatric Acute Lymphoblastic Leukemia
Górecki, M., Kozioł, I., Kopystecka, A., Budzyńska, J., Zawitkowska, J., & Lejman, M. (2023) · Biomedicines · doi:10.3390/biomedicines11030821 · Cited by 69
“Topoisomerase complex with irinotecan prevents the release of topoisomerase and disables the relegation of the nicked strand, which ultimately leads to cell death [102].”
BackgroundSubstances of Natural Origin in Medicine: Plants vs. Cancer
Gielecińska, A., Kciuk, M., Mujwar, S., Çelik, İ., Kołat, D., Kałuzińska‐Kołat, Ż., & Kontek, R. (2023) · Cells · doi:10.3390/cells12070986 · Cited by 84
“This is a fully controlled and reversible transesterification reaction, resulting in DNA relaxation [82].”
BackgroundSelf-citationAn Organ‐on‐Chip Platform for Simulating Drug Metabolism Along the Gut–Liver Axis
Lucchetti, M., Aina, K. O., Grandmougin, L., Jäger, C., Escriva, P. P., Letellier, E., Mosig, A. S., & Wilmes, P. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202303943 · Cited by 79
Recent advances in biotin-based therapeutic agents for cancer therapy
Wang, C., Xiu, Y., Zhang, Y., Wang, Y., Xu, J., Yu, W., & Xing, D. (2024) · Nanoscale · doi:10.1039/d4nr03729d · Cited by 70
Vitamins and fatty acids against chemotherapy-induced intestinal mucositis
Alcorta, A., López‐Gómez, L., Capasso, R., & Abalo, R. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108689 · Cited by 62
Fan, X., Lin, X., Ruan, Q., Wang, J., Yang, Y., Sheng, M., Zhou, W., Kai, G., & Hao, X. (2022) · Industrial Crops and Products · doi:10.1016/j.indcrop.2022.115270 · Cited by 61
Khodair, A. I. A., El-hallouty, S. M., Cagle-White, B., Aziz, M. H. A., Hanafy, M. K., Mowafy, S., Hamdy, N. Μ., & Kassab, S. E. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116049 · Cited by 58
Obesity-Associated Colorectal Cancer
Gonzalez-Gutierrez, L., Motiño, O., Barriuso, D., de la Puente-Aldea, J., Alvarez-Frutos, L., Kroemer, G., Palacios, R., & Senovilla, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168836 · Cited by 60
“SN38 is a topoisomerase I inhibitor that produces DNA breaks, triggering DNA damage checkpoint signaling (ataxia-telangiectasia mutated serine/threonine kinase (ATM)- checkpoint kinase 2 serine/threonine kinase (CHK2)-TP53) and thus leading to apoptosis [204].”
BackgroundHossain, S., Yousaf, M., Liu, Y., Chang, D., & Zhou, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.876183 · Cited by 54
Resistance to TOP-1 Inhibitors: Good Old Drugs Still Can Surprise Us
Kumar, S., & Sherman, M. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087233 · Cited by 50
“The presence of a genetic variant of SLCO1B1 (521T > C) was correlated with higher toxicity in metastatic colorectal cancer patients treated with irinotecan as the first line of treatment [47,49,92].”
BackgroundInfluentialPD-1/PD-L1 and DNA Damage Response in Cancer
Kciuk, M., Kołat, D., Kałuzińska‐Kołat, Ż., Gawrysiak, M., Drozda, R., Çelik, İ., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040530 · Cited by 50
“This combined treatment increased the infiltration of CD8+ T lymphocytes into the tumor, capable of producing cytotoxic effects [124,125,127,128].”
BackgroundSelf-citationTetracycline antibiotics: Potential anticancer drugs
Li, J., Qin, Y., Zhao, C., Zhang, Z., & Zhou, Z. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175949 · Cited by 56
Protective effect of luteolin against chemical and natural toxicants by targeting NF‐κB pathway
Mahdiani, S., Omidkhoda, N., Heidari, S., Hayes, A. W., & Karimi, G. (2022) · BioFactors · doi:10.1002/biof.1876 · Cited by 50
“The drug has been used as an antineoplastic agent to treat colorectal, ovarian, and non-small cell lung cancers.(71) Irinotecan may contribute to intestinal mucositis and diarrhea, common side effects of anticancer drugs.”
BackgroundThe effective combination therapies with irinotecan for colorectal cancer
Chai, Y., Liu, J., Zhang, S., Li, N., Xu, D., Liu, W., Fu, R., & Tang, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1356708 · Cited by 55
Tumor-related Microbiome in the Breast Microenvironment and Breast Cancer
Wang, N., Sun, T., & Xu, J. (2021) · Journal of Cancer · doi:10.7150/jca.58986 · Cited by 42
“SN-38, an active metabolite of irinotecan, was converted to inactive SN38-G form by UDPglucuronosyltransferases (UGTs) and caused severe diarrhea, which was correlated with polymorphism in UGT1A1 and the diversity of gut bacteria [55, 58].”
BackgroundFathi‐karkan, S., Qindeel, M., Arshad, R., Moafian, Z., Ghazy, E., Rahdar, A., & Ghotekar, S. K. (2024) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2024.112028 · Cited by 44
Recent advancements in natural compounds for cancer therapy and prevention
Pavithra, R., Khan, M. R., & Khan, M. S. (2024) · Phytochemistry Reviews · doi:10.1007/s11101-024-09940-0 · Cited by 46
“This causes double-stranded DNA breakage and replication arrest, leading to programmed cell death due to ineffective DNA damage repair (Kciuk et al. 2020).”
Kciuk, M., Gielecińska, A., Kałuzińska‐Kołat, Ż., Yahya, E. B., & Kontek, R. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189124 · Cited by 46
Self-citationNatural compounds targeting nuclear receptors for effective cancer therapy
Hegde, M., Girisa, S., Naliyadhara, N., Kumar, A., Alqahtani, M. S., Abbas, M. A. E., Mohan, C. D., Warrier, S. R., Hui, K. M., Rangappa, K. S., et al. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10068-w · Cited by 43
Wang, Q., Liu, J., Yang, M., Zhou, J., Li, Y., Zheng, J., Jia, H., Yue, S., Le, Y., Su, Y., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02321-9 · Cited by 44
“Given that the primary mechanism of action of many chemotherapeutic agents involves interference with DNA metabolism, 52,53 we propose that drug-resistant cells counteract these effects by actively supplying abundant nucleic acid synthesis precursors through glycolysis, the PPP, one-carbon…”
Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice
Park, W., O'Connor, C. A., Bandlamudi, C., Forman, D., Chou, J. F., Umeda, S., Reyngold, M., Varghese, A. M., Keane, F., Balogun, F., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1483 · Cited by 34
Jang, J. Y., Kim, D., & Kim, N. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098457 · Cited by 37
“The approval for the use of irinotecan (Camptosar®) as a treatment for cervical, lung, and ovarian cancer was granted in Japan in 1994, and in 1995 and 1996, it was approved for use in Europe and the United States, respectively [25] (Figure 1C).”
BackgroundIrinotecan-Induced Steatohepatitis: Current Insights
Han, J., Zhang, J., & Zhang, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.754891 · Cited by 31
“Irinotecan, which is a semi-synthetic and water-soluble camptothecin-derivative cytotoxic drug (2).”
BackgroundGynotoxic Effects of Chemotherapy and Potential Protective Mechanisms
Markowska, A., Antoszczak, M., Markowska, J., & Huczyński, A. (2024) · Cancers · doi:10.3390/cancers16122288 · Cited by 31
Clinical translation and landscape of superparamagnetic iron oxide nanoparticles
Li, Y., Barmin, R. A., Zhang, R., Kiessling, F. M., Lammers, T., & Pallares, R. M. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115756 · Cited by 42
Komedchikova, E. N., Kolesnikova, O. A., Syuy, A. V., Volkov, V. S., Deyev, S. M., Nikitin, M. P., & Shipunova, V. O. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.11.036 · Cited by 31
Establishment and Characterization of an Irinotecan-Resistant Human Colon Cancer Cell Line
Wu, Z., Yang, Y., Zeng, L., Patel, H. H., Bo, L., Lin, L., & Chen, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.624954 · Cited by 38
Albadari, N. G., Xie, Y., & Li, W. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1340401 · Cited by 37
“Irinotecan inhibits DNA TOP 1, resulting in misalignment and therefore inhibiting DNA replication and transcription (Cuya et al., 2017; Kciuk et al., 2020).”
BackgroundZhou, D., Zhai, X.-T., Zhang, L.-W., Xie, Z.-H., Wang, Y., Zhen, Y., Gao, R., & Miao, Q. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00584-z · Cited by 32
“Irinotecan is a common chemotherapeutic agent which has been widely used for many years in cancer treatment 33 .”
Gladkova, E. D., Nechepurenko, I. V., Bredikhin, R. A., Chepanova, A. A., Zakharenko, A. L., Luzina, O. A., Ilina, E. S., Dyrkheeva, N. S., Mamontova, E. M., Anarbaev, R. O., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197162 · Cited by 29
“The anticancer activity of Top1 poisons, camptothecin and its clinically important derivatives, topotecan and irinotecan [5,6], is based on their ability to bind to the covalent intermediate complex Top1/DNA and prevent the restoring of DNA integrity.”
BackgroundNovel FOXM1 inhibitor STL001 sensitizes human cancers to a broad-spectrum of cancer therapies
Raghuwanshi, S., Zhang, X., Arbieva, Z. H., Khan, I., Mohammed, H., Wang, Z., Dömling, A. S. S., Camacho, C. J., & Gartel, A. L. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01929-0 · Cited by 33
Local Breast Microbiota: A “New” Player on the Block
Vitorino, M. M., Costa, D. A., Vicente, R. S., Caleça, T., & Santos, C. (2022) · Cancers · doi:10.3390/cancers14153811 · Cited by 30
“Higher levels of Proteobacteria, present in much severe diarrhoea or inflammatory diseases, were also found in lapatinib treatment in rats coincident with the higher incidence of diarrhoea [12,82].”
BackgroundWang, C., Teng, X., Wang, C., Liu, B., Zhou, R., Xu, X., Qiu, H., Fu, Y., Sun, R., Liang, Z., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155040 · Cited by 31
Antibacterial activity of medicinal plants and their role in wound healing
Breijyeh, Z., & Karaman, R. (2024) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-024-00634-0 · Cited by 51
“[61] designed an experiment to explore the effects of five herbal extracts on wound healing, Bauhinia purpurea (inhibit inflammation, and act as analgesic and antipyretic) [60], Paeoniae rubrae (ameliorating inflammation by inhibiting glycogen synthase kinase 3β (GSK3β)) [55], Angelica dahurica…”
Gao, R., Yue, B., Lv, C., Geng, X., Yu, Z., Wang, H., Zhang, B., Ai, F., Wang, Z., Liu, D., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.09.018 · Cited by 31
“However, the clinical application of CPT11 is hampered by the onset of delayed diarrhea and consequential damage to the intestinal mucosa 3 .”
Development of heterocyclic-based anticancer agents: A comprehensive review
Al‐Jumaili, M. H. A., Bakr, E. A., Huessien, M. A., Hamed, A. S., & Muhaidi, M. J. (2025) · Heterocyclic Communications · doi:10.1515/hc-2022-0179 · Cited by 36
The Challenge of Combining Chemo- and Radiotherapy with Checkpoint Kinase Inhibitors
van Bijsterveldt, L., Durley, S. C., Maughan, T., & Humphrey, T. C. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3358 · Cited by 31
“Even though the clinical use of CPT was hindered due to severe toxicity and low solubility and stability issues, many other semisynthetic CPT derivatives, including irinotecan and topotecan, continue to be important anticancer agents (43).”
BackgroundThe role of gut microbiota in the development of colorectal cancer: a review
Koyande, N. P., Gangopadhyay, M., Thatikonda, S., & Rengan, A. K. (2022) · International Journal of Colorectal Disease · doi:10.1007/s00384-022-04192-w · Cited by 30
Data Driven Mathematical Model of FOLFIRI Treatment for Colon Cancer
Budithi, A., Su, S., Kirshtein, A., & Shahriyari, L. (2021) · Cancers · doi:10.3390/cancers13112632 · Cited by 28
Vignesh, A., Amal, T. C., Selvakumar, S., & Vasanth, K. (2023) · Health Sciences Review · doi:10.1016/j.hsr.2023.100115 · Cited by 38
Lerchen, H., Stelte‐Ludwig, B., Kopitz, C., Héroult, M., Zubov, D., Willuda, J., Schlange, T., Kahnert, A., Wong, H. H., Izumi, R. E., et al. (2022) · Cancers · doi:10.3390/cancers14020391 · Cited by 27
“VIP126, the modified CPT payload employed in VIP236, is a novel derivative of SN38, the clinically validated active metabolite of irinotecan (Camptosar®) [34].”
BackgroundMeng, J., Abu, Y. F., Zhang, Y., Zhou, Y., Xie, Y., Yan, Y., Tao, J., Ramakrishnan, S., Chen, C., & Roy, S. (2022) · British Journal of Pharmacology · doi:10.1111/bph.16020 · Cited by 27
“ent types of solid tumours by inhibiting DNA topoisomerase I (Kciuk et al., 2020).”
BackgroundYue, F., Zeng, X., Wang, Y., Fang, Y., Yue, M., Zhao, X., Zhu, R., Zeng, Q., Wei, J., & Chen, T. (2024) · BMC Microbiology · doi:10.1186/s12866-023-03152-w · Cited by 25
“As a result, the dosage and frequency of the drug are limited, and the therapeutic effect is reduced, affecting the patient’s prognosis [9].”
BackgroundZhang, X., Yang, Y., Wen, M., Zhong, F., Shu, X., Xu, R., Xiong, P., Zhou, Z., He, X.-Y., Tang, X., et al. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c09602 · Cited by 26
Sultana, R., Chen, S., Lim, E. H., Dent, R. A., & Chowbay, B. (2024) · BJC Reports · doi:10.1038/s44276-024-00106-1 · Cited by 27
Pharmacomicrobiomics in Anticancer Therapies: Why the Gut Microbiota Should Be Pointed Out
Conti, G., D’Amico, F., Fabbrini, M., Brigidi, P., Barone, M., & Turroni, S. (2022) · Genes · doi:10.3390/genes14010055 · Cited by 28
“A few years later, Zaharuddin and colleagues [92] determined the effect of consuming probiotics (Lactobacillus acidophilus, Lactococcus lactis, Lactobacillus casei, Bifidobacterium longum, B. bifidum, B. longum subsp. infantis) for 6 months on clinical outcomes and levels of pro-inflammatory cytokines (TNF-α, IFN-γ, I…”
BackgroundInfluentialCancer treatment: from traditional Chinese herbal medicine to the liposome delivery system
Fu, M., Han, X., Chen, B., Guo, L., Zhong, L., Hu, P., Pan, Y., Qiu, M., Cao, P., & Chen, J. (2022) · Acta Materia Medica · doi:10.15212/amm-2022-0035 · Cited by 26
“Moreover, IRI induces immunogenic cell death (ICD), which will help increase the immune response of tumor-specific antigen or increase damage-related molecular patterns [83].”
BackgroundThe role of gut microbial β-glucuronidases in carcinogenesis and cancer treatment: a scoping review
Hillege, L. E., Stevens, M. A. M., Kristen, P. A. J., de Vos‐Geelen, J., Penders, J., Redinbo, M. R., & Smidt, M. L. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-06028-2 · Cited by 23
Weighty matters: Unraveling the impact of obesity on colorectal cancer and nutritional interventions
Simancas‐Racines, D., Reytor-González, C., Frías-Toral, E., Katsanos, C. S., & Hidalgo, R. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.06.004 · Cited by 21
Loganathan, S., Govindasamy, M., Habila, M. A., & Manimaran, K. (2023) · Biocatalysis and Agricultural Biotechnology · doi:10.1016/j.bcab.2023.102905 · Cited by 22
A statistical framework for high-content phenotypic profiling using cellular feature distributions
Pearson, Y. E., Kremb, S., Butterfoss, G. L., Xie, X., Fahs, H., & Gunsalus, K. C. (2022) · Communications Biology · doi:10.1038/s42003-022-04343-3 · Cited by 19
“Irinotecan (IRI) is a chemotherapeutic agent that inhibits topoisomerase I activity, which in turn inhibits both DNA replication and transcription 49 .”
Sustained Drug Release from Dual‐Responsive Hydrogels for Local Cancer Chemo–Photothermal Therapy
Liu, Z., Koseki, Y., Suzuki, R., Dao, A. T. N., & Kasai, H. (2024) · Macromolecular Bioscience · doi:10.1002/mabi.202400413 · Cited by 21
Amniouel, S., & Jafri, M. S. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2023.1272206 · Cited by 22
“Irinotecan targets topoisomerase I which is essential for proper DNA topology during replication and transcription (Kciuk et al., 2020).”
BackgroundUnraveling the pathogenesis of myelosuppression and therapeutic potential of natural products
Nian, Q., Liu, R., & Zeng, J. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155810 · Cited by 23
Ren, S.-N., Zhang, Z.-Y., Guo, R.-J., Wang, D., Chen, F., Chen, X., & Fang, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i13.1911 · Cited by 22
Can immunotherapy reinforce chemotherapy efficacy? a new perspective on colorectal cancer treatment
He, X., Lan, H., Jin, K., & Liu, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1237764 · Cited by 23
Sun, R., Liang, Y., Zhu, S., Yin, Q., Bian, Y., Ma, H., Zhao, F., Yin, G., & Tang, D. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118038 · Cited by 18
Zheng, S., Li, M., Xu, W., Zhang, J., Li, G., Xiao, H., Liu, X., Shi, J., Xia, F., Tian, C., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.012 · Cited by 23
SATO, M., Han, Q., Kubota, Y., BARANOV, A., ARDJMAND, D., MIZUTA, K., Morinaga, S., Kang, B. M., Kobayashi, N., Bouvet, M., et al. (2023) · Anticancer Research · doi:10.21873/anticanres.16785 · Cited by 21
Fatemi, M., Meshkini, A., & Matin, M. M. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.129179 · Cited by 19
Romano, E., Netti, P. A., & Torino, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189896 · Cited by 17
“Sci. 2021, 22, x FOR PEER REVIEW 4 of 16 treat GBM.”
BackgroundInfluentialUGT1A1 and Sacituzumab Govitecan Toxicity: A Systematic Review and Meta‐Analysis
Russo, C. D., Asiimwe, I. G., Pushpakom, S. P., Palmieri, C., & Pirmohamed, M. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70060 · Cited by 17
Gençosman, S., Ceylanlı, D., Şehirli, A. Ö., Teralı, K., Bölükbaşı, F., Çetınel, Ş., & Sayıner, S. (2022) · Antioxidants · doi:10.3390/antiox11112219 · Cited by 17
Liang, Y., Su, T., Zhu, S., Sun, R., Qin, J., Yue, Z., Wang, X., Liang, Z., Tan, X., Bian, Y., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156562 · Cited by 17
Deep learning-driven drug response prediction and mechanistic insights in cancer genomics
Yu, G., & Fan, Q. (2025) · Scientific Reports · doi:10.1038/s41598-025-91571-2 · Cited by 25
“By combining IC50 data for Bendamustine from CTRPv2 and GDSC, we identified drugs highly correlated with Bendamustine, including Oxaliplatin 38 , Irinotecan 39 , Niraparib 40 , and Topotecan 41 (Fig.”
Krug, D. A., Tio, J., Abaci, A., Beurer, B., Brügge, S., Elsayad, K., Meixner, E., Park‐Simon, T., Smetanay, K., Winkelmann, F., et al. (2024) · Cancers · doi:10.3390/cancers16091649 · Cited by 16
“Mechanistically, the inhibition of DNA repair by topoisomerase inhibitors has been well studied [25,26].”
BackgroundLou, S., Chen, H., Cui, Z., Zhang, X., Zhu, C., Zhou, L., Ou, Y., & Zou, F. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1516449 · Cited by 16
Bacteroides intestinalis mediates the sensitivity to irinotecan toxicity via tryptophan catabolites
Hou, Y., Wu, H., Zhang, Z., Wang, J., Chen, Q., Lian, C., He, D., Li, Z., Wei, W., Lin, X., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-334699 · Cited by 15
Wang, B., Wu, S., Jia, S., Ruan, X.-Q., Sheng, C., & Zhou, Q. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00982 · Cited by 14
Cannabinoids and triple-negative breast cancer treatment
Dobovišek, L., Borštnar, S., Debeljak, N., & Brezar, S. K. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1386548 · Cited by 13
“Exatecan is primarily metabolized in the liver by hepatic P450 metabolism (CYP3A4 and CYP1A2) (180) and SN38 is metabolized in the liver by UDP-glucuronosyltransferase (UGT) (UGT1A1 and UGHT1A9) and UGT1A9 and other non-hepatic UGT enzymes (181).”
BackgroundZebrafish Xenograft Model for Studying Pancreatic Cancer-Instructed Innate Immune Microenvironment
Wang, X., Li, W., Jiang, H., Ma, C., Huang, M., Wei, X., Wang, W., & Jing, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126442 · Cited by 16
“Irinotecan treatment significantly inhibited tumor growth and also suppressed innate immune cells as previously suggested [45].”
BackgroundRed Blood Cells-Based Vaccines for Ameliorating Cancer Chemoimmunotherapy
Su, L., Hao, Y., Li, R., Pan, W., Ma, X., Weng, J., & Min, Y. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.10.001 · Cited by 14
Zhou, T., Liu, Y., Lei, K., Liu, J., Hu, M., Guo, L., Guo, Y., & Ye, Q. (2023) · Molecules · doi:10.3390/molecules28041577 · Cited by 14
Hegedüs, L., Okumus, Ö., Mairinger, F. D., Plönes, T., Reuter, S., Schüler, M., Welt, A., Vega-Rubín-de-Celis, S., Theegarten, D., Bánkfalvi, Á., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.03.003 · Cited by 14
Microbiome-driven precision medicine: advancing drug development with pharmacomicrobiomics
Ebadpour, N., Abavisani, M., & Sahebkar, A. (2025) · Journal of drug targeting · doi:10.1080/1061186x.2025.2509283 · Cited by 18
“…its active form, SN-38 (7-ethyl-1 0-hydroxycamptothecin), followed by conjugation by the enzyme uridine diphosphate glucuronosyl transferase-1A (UGt1A1) to yield an inactive metabolite, SN-38G (SN-38 glucuronide). the inactive form is primarily eliminated in bile in the intestines (Figure 1) [44].”
Kumar, S., Gahramanov, V., Patel, S. H., Yaglom, J. A., Kaczmarczyk, L. S., Alexandrov, I. A., Gerlitz, G., Salmon‐Divon, M., & Sherman, M. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108717 · Cited by 17
“Unlike almost any anti-cancer drug, irinotecan is not effective against stage I or II cancers and become quite effective in advanced and metastatic cancers (Köhne et al, 2003; Fujita et al, 2015; Vanhoefer et al, 2016; de Man et al, 2018; Kciuk et al, 2020).”
BackgroundSilverman, L., Bhatti, G., Wulff, J. E., & Moffitt, M. G. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00005 · Cited by 18
Yue, B., Gao, R., Zhao, L., Liu, D., Lv, C., Wang, Z., Ai, F., Zhang, B., Yu, Z., Geng, X., et al. (2025) · Advanced Science · doi:10.1002/advs.202411052 · Cited by 23
Soroushmanesh, M., Dinari, M., & Jalali, H. (2025) · Results in Engineering · doi:10.1016/j.rineng.2025.105919 · Cited by 12
Single protein encapsulated SN38 for tumor-targeting treatment
Yu, C., Huang, F., Wang, K., Liu, M., Chow, W. A., Ling, X., Li, F., Causey, J., Huang, X., Cook‐Wiens, G., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04778-0 · Cited by 14
“These intrinsic limitations of irinotecan significantly reduce its clinical potential [6].”
BackgroundInnovative Nanoparticulate Strategies in Colon Cancer Treatment: A Paradigm Shift
Yadav, R., Bhawale, R., Srivastava, V., Pardhi, E. R., Bhalerao, H. A., Sonti, R., & Mehra, N. K. (2024) · AAPS PharmSciTech · doi:10.1208/s12249-024-02759-0 · Cited by 13
“2) [47].”
Semisynthetic phytochemicals in cancer treatment: a medicinal chemistry perspective
Arora, M., Singh, A. K., Kumar, A. M., Singh, H., Pathak, P., Grishina, M., Yadav, J. P., Verma, A., & Kumar, P. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00317a · Cited by 15
Anticancer potential of daidzin: a comprehensive literature review
Islam, M. T., Rahman, M. T., Mia, E., Kamli, H. M., Hasan, A. M. W., Uddin, M. B., Sayeed, M. A., Hasan, A., Emon, Y., Yana, N. T., et al. (2025) · Medical Oncology · doi:10.1007/s12032-025-02839-6 · Cited by 15
Nguyen, M. K., Nguyen, V. P., Yang, S. Y., Min, B. S., & Kim, J. A. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107230 · Cited by 12
SATO, M., MIZUTA, K., Han, Q., Morinaga, S., Kang, B. M., Kubota, Y., Mori, R., BARANOV, A., Kobayashi, K., ARDJMAND, D., et al. (2024) · In Vivo · doi:10.21873/invivo.13539 · Cited by 12
“However, IRN has severe toxicity such as neutropenia and diarrhea, which is dose-limiting (9, 10).”
BackgroundGirod, M., Geisler, A., Hinze, L., Elsner, L., Dieringer, B., Beling, A., Kurreck, J., & Fechner, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115618 · Cited by 11
“Its active metabolite SN-38 interacts with the Topoisomerase–DNA complex, forming a Topoisomerase I-Irinotecan/SN-38-DNA ternary complex, which inhibits the process of DNA replication in tumor cells by inducing DNA double-stand break formations [7].”
BackgroundHuang, P., Li, W., Guan, J., Jia, Y., Wang, D., Chen, Y., Xiao, N., Ou, S., Wang, Y., & Yang, B. (2025) · Journal of Functional Biomaterials · doi:10.3390/jfb16010025 · Cited by 13
Jurič, A., Karačonji, I. B., & Kopjar, N. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109672 · Cited by 13
Vagiannis, D., Zhang, Y., Budagaga, Y., Novotná, E., Skarka, A., Kammerer, S., Küpper, J., & Hofman, J. (2021) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2021.115823 · Cited by 13
Anti-Colorectal Cancer Effects of a Novel Camptothecin Derivative PCC0208037 In Vitro and In Vivo
Li, M., Wang, L., Wei, Y., Wang, W., Liu, Z., Zuo, A., Liu, W., Tian, J., & Wang, H. (2022) · Pharmaceuticals · doi:10.3390/ph16010053 · Cited by 13
“After excreted via the biliary ducts into the gastrointestinal (GI) tract, SN-38G can be regenerated into SN-38 by the bacterial enzyme β-glucuronidase (GUS), which results in toxicity to the intestinal cells causing mucositis and diarrhea [9].”
BackgroundMACC1 and Gasdermin-E (GSDME) regulate the resistance of colorectal cancer cells to irinotecan
Cheng, M., Yang, B.-B., Zhan, Z., Lin, S., Fang, Z., Gao, Y., & Zhou, W. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.06.002 · Cited by 11
Cazzaniga, M., Zonzini, G. B., Pierro, F. D., Palazzi, C. M., Cardinali, M., & Bertuccioli, A. (2023) · Pathology & Oncology Research · doi:10.3389/pore.2023.1611300 · Cited by 12
Metadata
- Authors
- Kciuk, M., Marciniak, B., & Kontek, R.
- Affiliations
- University of Łódź (PL)
- Corresponding author
- Kciuk, Mateusz
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-07-12
- Volume
- 21
- Issue
- 14
- Pages
- 4919
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7404108
- OpenAlex
- W3041813955
- Cited by
- 266
- References
- 136
- Citations by year
- 2026: 29 · 2025: 76 · 2024: 66 · 2023: 50 · 2022: 29 · 2021: 13 · 2020: 3
- FWCI
- 2.27
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- irinotecan, camptothecin, SN-38, pharmacogenetics, drug metabolism, drug toxicity, combination chemotherapy, liposomal formulation, dendrimers, nanoparticles, drug resistance, anticancer agents
- MeSH terms
- Irinotecan, Antineoplastic Combined Chemotherapy Protocols, DNA, Neoplasm, Dosage Forms, Drug Compounding, Drug Synergism, Female, Humans, Male, Models, Molecular, Neoplasm Proteins, Neoplasms, Nucleic Acid Conformation, Prodrugs, Protein Conformation, Molecular Structure, Drug Resistance, Neoplasm, Polymorphism, Single Nucleotide, Topoisomerase I Inhibitors, Activation, Metabolic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.